Abacavir and lamivudine for the treatment of human immunodeficiency virus

Bibliography

• Bhaskaran K, Hamouda O, Sannes M, Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Palmer S, Maldarelli F, Wiegand A, Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008;105:3879-8
   PubMed Web of Science ®Google Scholar
• Benveniste O, Flahault A, Rollot F, Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005;191:1670-9
   PubMed Web of Science ®Google Scholar
• Marziali M, De Santis W, Carello R, T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART. AIDS 2006;20:2033-41
   PubMed Web of Science ®Google Scholar
• Aiuti F, Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006;8:88-97
   PubMed Web of Science ®Google Scholar
• Das M, Chu PL, Santos GM, Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010;5(6):e11068
   PubMed Web of Science ®Google Scholar
• Montaner JS, Lima VD, Barrios R, Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376(9740):532-9
   PubMed Web of Science ®Google Scholar
• Baker K, Lou Y, Yuen G, The bioequivalence and effect of food of a new once-a-day fixed dose combination tablet of ABC (ABC) and 3TC (3TC) [abstract no. A-458]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); October 30 – November 2 2004; Washington, DC
   Google Scholar
• Wang LH, Chittick GE, McDowell JA. Single-dose pharmaco- kinetics and safety of ABC (1592U89), zidovudine, and 3TC administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother 1999;43(7):1708-15
   PubMed Web of Science ®Google Scholar
• Margolis D, Heredia A, Gaywee J, ABC and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999;15:362-37
   Google Scholar
• Hong M, Schlichter L, Bendayan R. A Na(+)-dependent nucleoside transporter in microglia. J Pharmacol Exp Ther 2000;292:366-74
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (US). Ziagen (ABC sulfate): prescribing information [online]. Available from: http://us.gsk.com/
   Google Scholar
• Drusano GL, Bilello PA, Symonds WT, Pharmacodynamics of ABC in an in vitro hollow-fiber model system. Antimicrob Agents Chemother 2002;46:464-70
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Fletcher C, Steady state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009;53(4):1532-8
   PubMed Web of Science ®Google Scholar
• Bruno R, Regazzi MB, Ciappina V, Comparison of the plasma pharmacokinetics of 3TC during twice and once daily administration in patients with HIV. Clin Pharmacokinet 2001;40(9):695-700
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Lou Y, Bumgarner NT, Equivalent steady-state pharmacokinetics of 3TC in plasma and 3TC triaphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 mg twice daily. Antimicrob Agents Chemother 2004;48(1):176-82
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline (US). Epivir (3TC): prescribing information [online]. Available from: http://us.gsk.com/
   Google Scholar
• Eron J Jr, Yeni P, Gathe J Jr, The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with ABC-3TC, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368(9534):476-82
   PubMed Web of Science ®Google Scholar
• Carosi G, Lazzarin A, Stellbrink HJ, Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with ABC/3TC once daily in antiretroviral-naive HIV-1-infected adult subjects. HIV Clin Trials 2009;10(6):356-67
   PubMed Web of Science ®Google Scholar
• Squires KE, Young B, DeJesus E, Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with ABC/3TC after initial suppression with ABC/3TC plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010;24:2019-27
   PubMed Web of Science ®Google Scholar
• Young B, Vanig T, Dejesus E, A pilot study of ABC/3TC and raltegravir in antiretroviral-naive HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 2010;11(5):260-9
   PubMed Web of Science ®Google Scholar
• Genebat M, Ruiz-Mateos E, Pulido I, Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr HIV Res 2010;8(6):482-6
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, ABC versus zidovudine combined with 3TC and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004;39(7):1038-46
   PubMed Web of Science ®Google Scholar
• MacArthur RD, Chen L, Peng G, Efficacy and safety of ABC plus 3TC versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibi- tor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clin Trials 2004;5:361-70
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Finec D, Randomized, double-blind, placebo-matched, multicenter trial of ABC/3TC or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-56
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, ABC–3TC versus tenofovir–emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-40
   PubMed Web of Science ®Google Scholar
• Daar E, Tierney C, Fischl M, ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients [abstract 59LB]. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010); 16 – 19 February 2010; San Francisco
   Google Scholar
• Chowers M, Gottesman BS, Leibovici L, Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2010;29(7):779-86
   PubMed Web of Science ®Google Scholar
• Hetherington S, McGuirk S, Powell G, Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor ABC. Clin Ther 2001;23:1603-14
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor ABC. Lancet 2002;359:727-32
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M, Genetic variations in HLA-B region and hypersensitivity reactions to ABC. Lancet 2002;359:1121-2
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Wong GA, Kaul R, Clinical and immunogenetic correlates of ABC hypersensitivity. AIDS 2005;19:979-98
   PubMed Web of Science ®Google Scholar
• Hughes AR, Mosteller M, Bansal AT, Association of genetic variations in HLA-B region with hypersensitivity to ABC in some, but not all, populations. Pharmacogenomics 2004;5:203-11
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Gaudieri S, Predisposition to ABC hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180-5
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, HLA-B*5701 Screening for hypersensitivity to ABC. N Engl J Med 2008;358(6):568-79
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed ABC hypersensitivity in white and black patients. Clin Infect Dis 2008;46(7):1111-18
   PubMed Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417-26
   PubMed Web of Science ®Google Scholar
• D:A:D study group; Strategies for Management of Anti-Retroviral Therapy/INSIGHT. Use of nucleoside reerse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22(14):F17-24
   Web of Science ®Google Scholar
• Brothers C, Hernandez JE, Cutrell AG, Risk of myocardial infarction and ABC therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51(1):20-8
   PubMed Web of Science ®Google Scholar
• Lang S, Mary-Krause M, Cotte L, Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.Clinical Epidemiology Group of the French Hospital Database on HIV. Arch Intern Med 2010;170(14):1228-38
   PubMedGoogle Scholar
• Martinez E, Larrousse M, Podzamczer D, ABC-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010;24(3):F1-9
   PubMed Web of Science ®Google Scholar
• Sinn K, Richardson R, Carr A. Lower arterial stiffness and Framingham score after switching ABC to tenofovir in men at high cardiovascular risk. AIDS 2010;24(15):2403-5
   PubMed Web of Science ®Google Scholar
• Ding X, Andraca-Carrera E, Cooper C, No Association of myocardial infarction with ABC use: findings of an FDA meta-analysis [abstract O-1004]. 18th Conference on Retroviruses and Opportunistic Infections Boston; February 27 – March 2 2011
   Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, Randomized comparison of renal effects, efficacy, and safety with once-daily ABC/3TC versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55(1):49-57
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas J, Comparison of changes in bone density and turnover with ABC-3TC versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51(8):963-7
   PubMed Web of Science ®Google Scholar